TABLE 2.
Neutralization of two glycosylation mutants using a panel of 10 MAbs capable of neutralizing SIV239-derived strainsa
| Viral strain | MAb IC50 titer (ng/μl)
|
|||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| 1.9C | 1.10A | 3.4E | 3.10A | 3.11H | 5.5B | 22A | 59C | E31 | C26 | |
| SIV239 | >14.6 | >62.5 | >26.9 | >39.8 | >80 | >16 | >Neat | >Neat | >41.8 | >50 |
| g3,11 | >14.6 | >62.5 | >26.9 | >39.8 | >80 | >16 | >Neat | >Neat | >41.8 | >50 |
| g19,20,22,23 | >14.6 | >62.5 | >26.9 | >39.8 | >80 | >16 | >Neat | >Neat | >41.8 | >50 |
| SIV316 | 0.001 | 0.004 | 0.002 | 0.1 | 0.005 | 0.04 | ND | ND | 0.0002 | 0.0008 |
See references 9 and 12. The titers are IC50 for each antibody against WT SIV239, g3,11, and g19,20,22,23. The MAbs have the following specificities based upon competition studies (9): 1.10A, V4; C26, V4; E31, competition group VI; 1.9C, competition group VI; 3.4E, competition group V; 3.11H, V3; 5.5B, V2; 3.10A, V1; 59C2, V2 (positions 171 to 190); and 22A, V1 (positions 111 to 130). The first eight MAbs were purified with known concentrations generously provided by James Robinson. The last two MAbs (59C2 and 22A) were hybridoma supernatants generously provided by James Hoxie. The 50% neutralization values for SIV316 are derived from the work of Johnson et al (22). ND, not done.